Office Policies

Streamline your visit by accessing and completing our convenient online patient forms, saving you time and ensuring a smooth experience during your appointment.

APPOINTMENT RESPONSIBILITIES

You are responsible for attending all scheduled appointments. If you cannot keep a scheduled appointment, you must notify our office to cancel or reschedule at least 24 hours prior to the appointment time.

FINANCIAL FEES AND OBLIGATIONS

Before initiating treatment, Innovative Treatment Centers, LLC (“the Practice”) will discuss estimated costs and payment options with you.

• Insurance Clients:
• Services will be billed to your insurance company.
• It is your responsibility to verify insurance benefits and notify the office if there are any changes in coverage.
• You are responsible for any deductible, co-pay, co-insurance, financial responsibility, and/or remaining balance that your insurance does not cover. These payments are due at the time of service.
• Medicaid Clients:
• Medicaid recipients are exempt from any financial obligations.
• Missed or late-cancellation appointments will not be billed to Medicaid clients.
• Private Insurance/Self-Pay Clients:
• Payment is required before initial and subsequent appointments for all services (e.g., psychotherapy, medication management, bariatric assessments, ADHD testing, etc.).
• Failure to pay fees and/or co-payments may result in the cancellation of future appointments until balances are satisfied.
• Updating Information:
• You are responsible for keeping your address, phone number, and insurance information up to date.

FEE SCHEDULE

1. Initial Psychiatric Evaluation: $300.00
2. Spinal Cord Stimulator/Bariatric Surgery Evaluation: $300.00
3. ADHD Testing: $250.00
4. Psychotherapy Sessions (including Pain Reprocessing Therapy and EMDR, 60 min): $180.00
5. Medication Management Visits: $165.00 (Fees may vary if additional services are provided.)

MISCELLANEOUS SERVICES & FEES

• Forms, Letters, and Record Reviews:
• Forms, letters, and record reviews requiring significant time outside of sessions will incur a fee of $75 per hour.
• Please allow 48 to 72 business hours for completion.
• Court Hearings, Telephone Correspondence, and Prior Authorizations: Fees vary depending on the time required.

CANCELLATIONS AND NO-SHOW POLICY

Due to HIPAA regulations and confidentiality, sessions must take place in a private, therapeutic setting. If the session cannot proceed due to an unsuitable environment, it will be marked as a late cancellation and charged accordingly.

• Grace Period: There is a 15-minute grace period for each session. After this, the session will be marked as a no-show and incur a $75.00 fee for private insurance/self-pay patients.
• Late Cancellations/No-Shows:
• If you need to cancel or reschedule an appointment, you must provide at least 24 hours’ notice (weekends not included).
• If the appointment is on Monday, cancellations must be made by the same hour on the preceding Friday.
• Failure to cancel or reschedule within the required timeframe will result in a $75.00 no-show/late cancellation fee for private insurance and self-pay clients.
• Medicaid/Medicare Clients: Appointments missed without 24-hour notice will be marked as no-call/no-show but will not incur a fee.
• Repeated No-Shows:
• Two (2) consecutive no-shows or late cancellations within 30 days may result in discharge from services with referrals to outside providers.
• To return for services, clients may reapply after 30 days and availability with their former provider is not guaranteed.

PAYMENT TERMS

• Full payment is expected at the beginning of each session unless alternative arrangements have been made.
• Accepted forms of payment include:
• Cash
• Personal checks (payable to “Innovative Treatment Centers, LLC”)
• Major credit/debit cards
• Returned Checks: A $50.00 service charge will apply to any returned checks.

PAST-DUE ACCOUNTS

If payment is 60 days past due, the Practice reserves the right to:

• Utilize legal resources such as collection agencies or small claims court to obtain payment.

NOTICE OF CHANGES

Fees, policies, and terms are subject to change at any time. Clients will be notified at least 30 days in advance of any fee increases.

Thank you for choosing Innovative Treatment Centers, LLC.
We are committed to providing exceptional mental health and addiction treatment services. Please feel free to contact our office if you have any questions regarding these policies.

At Innovative Treatment Centers, the use of controlled substances, including benzodiazepines and stimulants, is carefully regulated and monitored. Medications such as Alprazolam, Clonazepam, Lorazepam (benzodiazepines), and Adderall XR, Concerta (stimulants) can be effective in managing anxiety, ADHD, and other conditions. Still, they require frequent monitoring and must be part of a comprehensive, evidence-based wellness plan.

Benzodiazepine Use Policy

While Innovative Treatment Centers does not have a strict “no benzodiazepine” policy, it is important to note that:

• Benzodiazepines will only be used for FDA-approved indications and for short-term or temporary management, unless extenuating circumstances are clearly documented.
• Benzodiazepines will not be prescribed for individuals who are concurrently prescribed opioids (whether for pain management or as part of medication-assisted treatment) or other central nervous system (CNS) depressants, due to the significant risk of respiratory depression, overdose, and death.
• The use of benzodiazepines may be re-evaluated periodically to assess continued clinical necessity and appropriateness.

Monitoring and Compliance Requirements

• Controlled substances will not be refilled early and cannot be refilled if the patient is not reasonably compliant with appointments.
• Innovative Treatment Centers utilizes the Maryland Prescription Drug Monitoring Program (PDMP) to review a patient’s controlled substance prescription history. The PDMP is a state-mandated database that enables providers to:
• Identify any potential misuse, abuse, or diversion of medications.
• Prescribe medications more safely and effectively by evaluating past and current prescriptions.

Behavioral Expectations and Grounds for Discontinuation

To ensure the safety and integrity of treatment:

• Aggressive, inappropriate, or manipulative behaviors related to the prescribing of controlled substances will result in an immediate and safe taper of medication, consistent with clinical guidelines.
• Non-compliance with appointments, staff harassment, or aggressive behavior will lead to a medically safe discontinuation and immediate discharge from the practice.
• Failure to adhere to the terms of the controlled substance treatment agreement may also result in the discontinuation of medication and termination of care.

Commitment to Safety and Responsible Prescribing

At Innovative Treatment Centers, we prioritize the safety and well-being of our patients by ensuring that the use of controlled substances, including benzodiazepines, is part of a comprehensive treatment plan that emphasizes safety, compliance, and evidence-based care. We reserve the right to discontinue treatment if clinical concerns arise regarding misuse, safety, or non-compliance with practice policies.

Innovative Treatment Centers, LLC (ITC) offers evidence-based medication-assisted treatment (MAT) for opioid use disorder (OUD) using Suboxone (buprenorphine/naloxone) and Sublocade/Brixadi (extended-release buprenorphine) as part of a comprehensive treatment plan. Our goal is to ensure safe, effective, and regulated use of these medications to support long-term recovery.

Eligibility and Treatment Guidelines

• Initial Evaluation: All patients undergo a complete assessment, including medical history and substance use evaluation.
• Informed Consent: Patients must sign an agreement outlining the risks, benefits, and responsibilities before starting treatment.
• PDMP Review: Providers review the Maryland Prescription Drug Monitoring Program (PDMP) before prescribing or administering medications.

Suboxone (Buprenorphine/Naloxone) Guidelines

• Induction & Stabilization: Initial dosing is monitored closely, with frequent follow-ups.
• Maintenance & Monitoring: Random urine drug screens (UDS) and pill counts are required to ensure compliance.
• Refill Policy: No early refills or replacement for lost, stolen, or damaged medication.

Sublocade (Extended-Release Buprenorphine) Guidelines

• Transition to Sublocade: Patients stabilized on Suboxone for at least 7 days may transition to Sublocade.
• Injection Protocol: Monthly Sublocade injections are administered in the office.

Patient Responsibilities

• Attend all scheduled appointments and comply with treatment plans.
• Participate in counseling and therapy as part of a comprehensive recovery plan.
• Report any side effects, concerns, or missed doses immediately.

Compliance and Discontinuation

• Non-Compliance or Diversion: Misuse or diversion of medication may lead to termination of treatment and discharge from the program.
• Missed Appointments: Failure to comply with treatment or attend appointments may result in discontinuation of services.

Special Considerations

• Pregnant patients may be transitioned to buprenorphine monotherapy.
• Patients with co-occurring psychiatric disorders will receive integrated care.

Acknowledgment

All patients must sign a Medication Treatment Agreement confirming their understanding of these policies.

For questions or concerns about our Suboxone/Sublocade policy, please contact our office.